<?xml version="1.0" encoding="UTF-8"?>
<p>The protease inhibitor lopinavir has been used—together with a small booster dose of ritonavir—to treat patients with COVID-19 in the current pandemic. Five of 18 patients with worsening clinical symptoms received this medication in a Singapore hospital. Improvement was seen in three patients, but not in the other two. Details of the disease course were published, but yielded no clear evidence for the potential efficacy of lopinavir (
 <xref rid="R12" ref-type="bibr">12</xref>). In Wuhan, 41 (21%) of 181 patients were treated with lopinavir/ritonavir, but no decrease in virus excretion was seen (
 <xref rid="R13" ref-type="bibr">13</xref>).
</p>
